Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vir Biotechnology, Inc. (VIR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/03/2023 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results – Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of Vir’s innate immunity small molecule platform –"
07/20/2023 8-K Quarterly results
05/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
03/08/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Vir Biotechnology, Inc",
"Amended and Restated Bylaws of Vir Biotechnology, Inc"
02/23/2023 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results – Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of sotrovimab collaboration revenue recognized in 2022 – – Strong balance sheet expected to fund Vir’s robust portfolio through major inflection points with the flexibility to evaluate external opportunities – SAN FRANCISCO, FEBRUARY 23, 2023"
02/22/2023 8-K Other Events  Interactive Data
02/13/2023 8-K Quarterly results
01/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/03/2022 8-K Quarterly results
10/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats"
08/09/2022 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results – More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years – – Company provides update on COVID-19 development program and outlines multiple anticipated value drivers from its robust pipeline – SAN FRANCISCO, August 9, 2022"
08/04/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/14/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/05/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant"
02/24/2022 8-K Quarterly results
12/22/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
11/04/2021 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results – To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized – – Anticipated fourth quarter milestones include: topline sotrovimab intramuscular administration data, new hepatitis B data at AASLD, and initial HIV vaccine immunology data –"
09/29/2021 8-K Other Events  Interactive Data
08/05/2021 8-K Quarterly results
06/28/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy